



Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

August 28, 2023

CHICAGO--(BUSINESS WIRE)--Aug. 28, 2023-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 9:30am Eastern Time.

A live webcast of the event will be available on the 'Events & Presentations' section of Xeris' Investor Relations website at <https://xerispharma.com/investor-relations> or <https://journey.ct.events/view/773cc0a3-0963-44b6-8523-1d257c8286d0> A replay of the webcast will be available for 60 days.

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke[®], a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis[®], a proven therapy for primary periodic paralysis; and Recorlev[®] for the treatment of endogenous Cushing's syndrome. Xeris has a pipeline of development and partnered programs using its formulation sciences, XeriSol[™] and XeriJect[™], to support long-term product development and commercial success.

Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow Xeris on [Twitter](#), [LinkedIn](#) or [Instagram](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230828934661/en/): <https://www.businesswire.com/news/home/20230828934661/en/>

Investor Contact

Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
away@xerispharma.com

Source: Xeris Biopharma Holdings, Inc.